TG Therapeutics (TGTX) News Today $35.17 +0.17 (+0.49%) Closing price 04:00 PM EasternExtended Trading$35.11 -0.06 (-0.17%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TGTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics StockJune 17 at 6:31 PM | benzinga.comAre Options Traders Betting on a Big Move in TG Therapeutics Stock?June 17 at 11:40 AM | msn.comYann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) StockJune 17 at 4:32 AM | insidertrades.comInsider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of StockTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) Director Yann Echelard sold 10,000 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director now directly owns 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.June 16 at 5:56 PM | marketbeat.comCantor Fitzgerald Predicts TG Therapeutics FY2026 EarningsJune 11, 2025 | americanbankingnews.comCantor Fitzgerald Estimates TG Therapeutics FY2026 EarningsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the biJune 10, 2025 | marketbeat.comGAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)GAMMA Investing LLC raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 6,905.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 179,130 shares of the biopharmaceutical company'sJune 9, 2025 | marketbeat.comTG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last MonthJune 7, 2025 | uk.finance.yahoo.comTG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 6, 2025 | globenewswire.comWellington Management Group LLP Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Wellington Management Group LLP cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 13.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,513 shares of the biopharmaceutical compaJune 6, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Two Sigma Advisers LP lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 95.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,700 shares of the biopharmaceuticalJune 6, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Trading Up 6.2% - Still a Buy?TG Therapeutics (NASDAQ:TGTX) Trading 6.2% Higher - Time to Buy?June 5, 2025 | marketbeat.comMackenzie Financial Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Mackenzie Financial Corp lessened its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,888 shares of the biopJune 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 7.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 272,370 shares oJune 1, 2025 | marketbeat.comNorthCrest Asset Manangement LLC Invests $448,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)NorthCrest Asset Manangement LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 14,890 shares of the biopharmaceutical company's stocMay 31, 2025 | marketbeat.comTG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual MeetingMay 30, 2025 | theglobeandmail.comMan Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX)Man Group plc purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 9,589 shares of the biopharmaceutical company's stocMay 29, 2025 | marketbeat.comTG Therapeutics: Estimates Could Soon Be Raised AgainMay 28, 2025 | seekingalpha.comBank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Bank of America Corp DE cut its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 86.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 230,939 shares of the biopharmaceutical compMay 28, 2025 | marketbeat.comTG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual MeetingMay 27, 2025 | globenewswire.comConnecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Connecticut Wealth Management LLC lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 46.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,782 shares of the biopharmaceMay 25, 2025 | marketbeat.comTwo Sigma Investments LP Trims Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Two Sigma Investments LP trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 43.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 606,208 shares of the bioMay 25, 2025 | marketbeat.comProShare Advisors LLC Acquires 12,951 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)ProShare Advisors LLC increased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,955 shares of the biopharmaceuMay 25, 2025 | marketbeat.comCaptrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Captrust Financial Advisors trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 75.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,562 shares of the biopharmaceutical company's stock after sellingMay 24, 2025 | marketbeat.comCastleark Management LLC Increases Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Castleark Management LLC lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 211,370 shares of the biopharmaceutical company's stocMay 23, 2025 | marketbeat.comDeutsche Bank AG Has $4.43 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Deutsche Bank AG lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,020 shares of the biopharmaceutical company's stock after acquiring an additional 4May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Has $80.71 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Soleus Capital Management L.P. raised its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,681,242 sharesMay 21, 2025 | marketbeat.comWexford Capital LP Invests $421,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)Wexford Capital LP acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 14,000 shares of the biopharmaceutical company's stock, valued at approximaMay 21, 2025 | marketbeat.comNuveen Asset Management LLC Has $54.15 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Nuveen Asset Management LLC lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 11.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,798,989 shares of the biopharmaceutical company'sMay 21, 2025 | marketbeat.comBalyasny Asset Management L.P. Invests $274,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)Balyasny Asset Management L.P. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 9,100 shares of the bMay 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by BNP Paribas Financial MarketsBNP Paribas Financial Markets trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 49.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,710 shares of the biopharmaceutMay 20, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesTG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy ratinMay 20, 2025 | marketbeat.comRafferty Asset Management LLC Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Rafferty Asset Management LLC reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,412 shares of the biopharmaceuticaMay 19, 2025 | marketbeat.comGotham Asset Management LLC Sells 64,333 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Gotham Asset Management LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 55.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,949 sharMay 19, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $2.55 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Jacobs Levy Equity Management Inc. reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 53.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 84,589 shares of the biopharmaceuticMay 18, 2025 | marketbeat.comNicholas Investment Partners LP Reduces Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Nicholas Investment Partners LP trimmed its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 84,147 shares of the biopharmaceutical companyMay 16, 2025 | marketbeat.comJ. Goldman & Co LP Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)J. Goldman & Co LP cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 81.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,036 shares of the biopharmaceutical company's stock aftMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Purchases Shares of 150,000 TG Therapeutics, Inc. (NASDAQ:TGTX)Integral Health Asset Management LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 150,000 shares of the biMay 14, 2025 | marketbeat.comBrevan Howard Capital Management LP Takes $453,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Brevan Howard Capital Management LP bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 15,042 shares of the biopharmaceutical company's stock, valued at appMay 12, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Algert Global LLCAlgert Global LLC lessened its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 52.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 49,061 shares of the biopharmaceutical company's stock after selling 5May 12, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Northern Trust CorpNorthern Trust Corp lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,532,929 shares of the biopharmaceutical company's stock after purchaMay 11, 2025 | marketbeat.comCantor Fitzgerald Predicts TG Therapeutics FY2025 EarningsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the bioMay 10, 2025 | marketbeat.comQ3 Earnings Forecast for TG Therapeutics Issued By B. RileyTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at B. Riley upped their Q3 2025 earnings per share estimates for shares of TG Therapeutics in a research note issued to investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical companyMay 10, 2025 | marketbeat.comDecoding TG Therapeutics Inc (TGTX): A Strategic SWOT InsightMay 10, 2025 | gurufocus.comAnalysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), TG Therapeutics (TGTX) and Vertex Pharmaceuticals (VRTX)May 9, 2025 | theglobeandmail.comTG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comB. Riley Brokers Lift Earnings Estimates for TG TherapeuticsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities research analysts at B. Riley boosted their Q2 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and investors on Monday, May 5th. B. Riley analyst M. Mamtani now expects that the biopharmaceutMay 9, 2025 | marketbeat.comCornerstone Select Advisors LLC Buys Shares of 63,270 TG Therapeutics, Inc. (NASDAQ:TGTX)Cornerstone Select Advisors LLC purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 63,270 shares of the biopharmaceutical company's stock, vaMay 9, 2025 | marketbeat.comLido Advisors LLC Takes $231,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Lido Advisors LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 7,680 shares of the biopharmaceutical company's stock, valued at approximately $231May 9, 2025 | marketbeat.comJ.P. Morgan Remains a Buy on TG Therapeutics (TGTX)May 8, 2025 | theglobeandmail.com Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Media Mentions By Week TGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼0.480.56▲Average Medical News Sentiment TGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼68▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News Summit Therapeutics News Genmab A/S News Intra-Cellular Therapies News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Qiagen News Moderna News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersThis is not your typical AI storyThe market’s biggest AI winners? You’ve never heard of them. Everyone’s obsessed with AI stocks like Nvidia...Market Traders Daily | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TGTX Stock Free TGTX Stock Alerts